Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of escitalopram in the treatment of depressive patients with acute coronary artery syndrome: a double-blind placebo-controlled trial

Trial Profile

Efficacy and safety of escitalopram in the treatment of depressive patients with acute coronary artery syndrome: a double-blind placebo-controlled trial

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Oct 2018

At a glance

  • Drugs Escitalopram (Primary)
  • Indications Depressive disorders
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EsDEPACS
  • Most Recent Events

    • 09 Oct 2018 Results presented at the 31st Annual Congress of the European College of Neuropsychopharmacology
    • 31 Aug 2018 Biomarkers information updated
    • 24 Jul 2018 Results published in the JAMA: the Journal of the American Medical Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top